Herve Hoppenot

Recent appearances

• 

  Ex-CEO of Incyte Hervé Hoppenot on 10x Growth, Biotech Cycles, and Breaking Bureaucracy | E58

  May 26, 2026 · 📺 FlotBio x Philip Hemme

  When Hervé joined Incyte in 2014, the launch of lead product Jakafi in the US was a little choppy. By the time he left in 2025, he had grown their revenue from $300 million to a whopping $5 billion. We also talk about the bureaucracy of Big Pharma, rare diseases, and why a biotech M&A supercycle isn’t as likely as you might think. --- Discover the best biotech companies in 🇪🇺 with the FlotBio Map. Use discount code FLOT20 before June 26 to get 20% off the pro version at https://bit.ly/flotbiomap --- ⭐️ ABOUT THE SPEAKER Prior to his time at Incyte, Hervé led the oncology business unit a…

  Watch on YouTube ↗

• 

  48th IC | HERVÉ HOPPENOT – Chairman and Chief Executive Officer of Incyte

  February 11, 2023 · 📺 Business Today

  Business Today presents the 48th International Conference The International Conference connects undergraduate students from around the world with top business executives. We connect the leaders of today with students like you — the leaders of tomorrow — to create a meaningful dialogue on the current business landscape. This year’s theme was “Community through Business.” Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer and was appointed Chairman of the Board of Directors in 2015. During Mr. Hoppenot’s tenure, the company has tripled the number of clinical candidat…

  Watch on YouTube ↗

• 

  Incyte Corporation CEO Herve Hoppenot on Creating a Culture Employees Love

  November 10, 2021 · 📺 Louis Carter: Leading Organizational Change

  Herve Hoppenot is Chairman of the Board, President, Chief Executive Officer of Incyte Corporation. Herve served as the President of Novartis Oncology, Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG, a pharmaceutical company, from January 2010 to January 2014. This pharma company offers benefits like 100 percent health insurance coverage for employees (95 percent for dependents) and, since 2017, parental leave for all situations. Incyte's world-class researchers are focused on transforming the treatment of cancer and inflammatory and autoimmune conditions and are adv…

  Watch on YouTube ↗

• 

  Galien Forum USA 2013 / Oncology: Newer Therapies

  January 13, 2021 · 📺 The Galien Foundation

  Chair: Dr. Paul A. Marks President Emeritus Laboratory Head of Cell Biology Memorial Sloan-Kettering Cancer Center, New York Panelists: Herve Hoppenot President Novartis Oncology Novartis Pharmaceuticals Corporation Dr. Carl H. June Director of Translational Research Abramson Cancer Center University of Pennsylvania Dr. Mark Kris Chief, Thoracic Oncology Services Memorial Sloan-Kettering Cancer Center Dr. Ira Mellman Vice President Research Oncology Genentech

  Watch on YouTube ↗

• 

  Incyte Corporation INCY CEO Hervé Hoppenot on Q4 2019 Results

  February 13, 2020 · 📺 Daily Earnings Calls

  Commercial Performance ...

  Watch on YouTube ↗

• 

  Hervé Hoppenot from Incyte

  June 25, 2019 · 📺 Select Greater Philadelphia

  From the Greater Philadelphia Life Sciences and Innovation Showcase on June 3, 2019.

  Watch on YouTube ↗